Pharma
Global Atherosclerosis Drugs Market Opportunities and Forecast 2020-2027
  • DLR2905
  • 05 February, 2022
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Atherosclerosis Drugs Market, By Type (Antiplatelet Medications, Cholesterol-Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta-Blockers, Angiotensin-converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Diuretics, Others), By Application (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and opportunities and forecast 2020-2027

Atherosclerosis Drugs Market Overview

The global atherosclerosis drugs market growth is driven by the rise within the prevalence of atherosclerosis and cardiovascular diseases, the growing variety of pipeline studies and therefore the rising involvement of key players in developing the treatment choices for atherosclerosis.

The increasing variety of pipeline studies coupled with technological advancements in treatment is predicted to drive market growth. The increasing variety of pipeline studies and therefore the rising involvement of key players in developing the treatment choices for hardening of the arteries are expected to propel the market of atherosclerosis.

Side effects associated with atherosclerosis drugs popularity the increasing popularity of generic drugs are likely to hamper the market growth. However, the side effects atherosclerosis and therefore the restricted efficacy are expected to hamper hardening of the arteries market growth. as an example, in Nov 2016, The Lancet, junction rectifier by Rory Collins, provided proof on medicine medical aid and therefore the method limitations. As per information, stains are related to associate hyperbolic incidence of diabetes and stroke. Stains tend to extend the chance of kind two diabetes in a dose-dependent mode.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Type, Application, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Pfizer Inc., GlaxoSmithKline PLC, Amgen Inc., Sanofi, Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., Novartis AG.


The covid-19 Impact on Atherosclerosis Drugs Market:

Whereas, the chemicals and accoutrements sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligences directly affected the chemical demand each around the world.
 
Atherosclerosis Drugs market Segment Overview


By Type, Cholesterol-lowering drugs segment is predicted to hold the largest share during this market section. The cholesterol-lowering medication embrace statins and fibrates. The dominant share of the section is attributed to the increasing prevalence of upset and high obesity, fleshiness globally. in line with the globe Health Organization, in 2020, thirty-nine million children under 5 years accounted overweight or weighty. an increased intake of energy-dense foods high in fat and sugars, and an upsurge in physical immobility due to the more and more static nature of many forms of work, changing modes of transportation, and increasing urbanization area unit factors propellent the high cholesterin rates and ultimately boosting the propelling growth.
 
By Application, hospital pharmacies are increasing across the world, owing to development in infrastructural and facilities. 
 
Market Analysis, Insights and Forecast – By Type
·       Antiplatelet Medications
·       Cholesterol-Lowering Medications
·       Fibric Acid and Omega-3 Fatty Acid Derivatives
·       Beta-Blockers
·       Angiotensin-converting Enzyme (ACE) Inhibitors
·       Calcium Channel Blockers
·       Diuretics
·       Others

Market Analysis, Insights and Forecast – By Application
·       Retail Pharmacies
·       Hospital Pharmacies
·       Online Pharmacies

Atherosclerosis Drugs Market Regional Overview

Region-wise, in terms of regions, North America is anticipated to dominate the general market throughout the forecast amount. The market growth is due to the factors like the presence of key players, high prevalence of vas diseases and induration of the arteries, established health care infrastructure, and key developments by market players, like product launch approvals, key mergers, and acquisitions.

Atherosclerosis Drugs Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Atherosclerosis Drugs Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Atherosclerosis Drugs are highlighted below.

·       In 2018, Bayer AG, unitedly with Janssen, acetylsalicylic acid started the clinical study for Rivaroxaban and acetylsalicylic acid to build up the insights in treatment patterns and to check results of Rivaroxaban (Xarelto) together with anodyne (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in 2021. Also, In could 2018, Amgen, inc received approval from the ecu Commission for REPATHA. This approval enabled the corporate to widen its product portfolio in Europe.

Atherosclerosis Drugs Market, Key Players -

·       Pfizer Inc.,
·       GlaxoSmithKline PLC,
·       Amgen Inc.,
·       Sanofi,
·       Mylan N.V.,
·       F.Hoffmann-La Roche Ltd.,
·       Janssen Pharmaceuticals, Inc.,
·       Bayer AG,
·       Merck & Co., Inc.,
·       Novartis AG.
 
 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Atherosclerosis Drugs Market during the forecast period?

A. Hospital Pharmacies market is expected to record a CAGR of ~ XX % during the forecast period.

Q2. Which segment is projected to hold the largest share in the Atherosclerosis Drugs Market?

A. Cholesterol-Lowering Medications segment is projected to hold the largest share in the Atherosclerosis Drugs Market.

Q3. What are the driving factors for the Atherosclerosis Drugs Market?

A. The increase in prevalence of atherosclerosis and cardiovascular diseases, the growing variety of pipeline studies , these are main factors driving the growth of automotive lighting market.

Q4. Which Segments are covered in the Atherosclerosis Drugs Market report?

A. Drug Type, Application and Region, these segments are covered in the Atherosclerosis Drugs Market report

Q5. Which are the prominent players offering Atherosclerosis Drugs Market?

A. Pfizer Inc.,GlaxoSmithKline PLC, Amgen Inc., Sanofi,Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., Novartis AG.
Atherosclerosis Drugs Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Atherosclerosis Drugs Market analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Type
        • 5.2.1. •Antiplatelet Medications
        • 5.2.2. •Cholesterol-Lowering Medications
        • 5.2.3. •Fibric Acid and Omega-3 Fatty Acid Derivatives
        • 5.2.4. •Beta-Blockers
        • 5.2.5. •Angiotensin-converting Enzyme (ACE) Inhibitors
        • 5.2.6. •Calcium Channel Blockers
        • 5.2.7. •Diuretics
        • 5.2.8. •Others
      • 5.3. Market Analysis, Insights and Forecast – By Application
        • 5.3.1. •Retail Pharmacies
        • 5.3.2. •Hospital Pharmacies
        • 5.3.3. •Online Pharmacies
      • 5.4. Market Analysis, Insights and Forecast – By Region
        • 5.4.1. North America
        • 5.4.2. Europe
        • 5.4.3. Asia Pacific
        • 5.4.4. Latin America, Middle East, and Africa

      6. North America Atherosclerosis Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Type
        • 6.2.1. •Antiplatelet Medications
        • 6.2.2. •Cholesterol-Lowering Medications
        • 6.2.3. •Fibric Acid and Omega-3 Fatty Acid Derivatives
        • 6.2.4. •Beta-Blockers
        • 6.2.5. •Angiotensin-converting Enzyme (ACE) Inhibitors
        • 6.2.6. •Calcium Channel Blockers
        • 6.2.7. •Diuretics
        • 6.2.8. •Others
      • 6.3. Market Analysis, Insights and Forecast – By Application
        • 6.3.1. •Retail Pharmacies
        • 6.3.2. •Hospital Pharmacies
        • 6.3.3. •Online Pharmacies
      • 6.4. Market Analysis, Insights and Forecast – By Country
        • 6.4.1. UK
        • 6.4.2. Germany
        • 6.4.3. France
        • 6.4.4. Italy
        • 6.4.5. Spain
        • 6.4.6. Russia
        • 6.4.7. Rest of Europe

      7. Asia Pacific Atherosclerosis Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Type
        • 7.2.1. •Antiplatelet Medications
        • 7.2.2. •Cholesterol-Lowering Medications
        • 7.2.3. •Fibric Acid and Omega-3 Fatty Acid Derivatives
        • 7.2.4. •Beta-Blockers
        • 7.2.5. •Angiotensin-converting Enzyme (ACE) Inhibitors
        • 7.2.6. •Calcium Channel Blockers
        • 7.2.7. •Diuretics
        • 7.2.8. •Others
      • 7.3. Market Analysis, Insights and Forecast – By Application
        • 7.3.1. •Retail Pharmacies
        • 7.3.2. •Hospital Pharmacies
        • 7.3.3. •Online Pharmacies
      • 7.4. Market Analysis, Insights and Forecast – By Country
        • 7.4.1. China
        • 7.4.2. India
        • 7.4.3. Japan
        • 7.4.4. Australia
        • 7.4.5. South East Asia
        • 7.4.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Atherosclerosis Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Type
        • 8.2.1. •Antiplatelet Medications
        • 8.2.2. •Cholesterol-Lowering Medications
        • 8.2.3. •Fibric Acid and Omega-3 Fatty Acid Derivatives
        • 8.2.4. •Beta-Blockers
        • 8.2.5. •Angiotensin-converting Enzyme (ACE) Inhibitors
        • 8.2.6. •Calcium Channel Blockers
        • 8.2.7. •Diuretics
        • 8.2.8. •Others
      • 8.3. Market Analysis, Insights and Forecast – By Application
        • 8.3.1. •Retail Pharmacies
        • 8.3.2. •Hospital Pharmacies
        • 8.3.3. •Online Pharmacies
      • 8.4. Market Analysis, Insights and Forecast – By Country
        • 8.4.1. Brazil
        • 8.4.2. Saudi Arabia
        • 8.4.3. UAE
        • 8.4.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Pfizer Inc.,
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. • GlaxoSmithKline PLC,
      • 9.6. •Amgen Inc.,
      • 9.7. • Sanofi,
      • 9.8. • Mylan N.V.,
      • 9.9. • F.Hoffmann-La Roche Ltd.,
      • 9.10. • Janssen Pharmaceuticals, Inc.,
      • 9.11. • Bayer AG,
      • 9.12. • Merck & Co., Inc.,

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      [email protected]

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934